APA

Swinnen L. J., O'Neill A., Imus P. H., Gujar S., Schiff D., Kleinberg L. R., Advani R. H., Dunbar E. M., Moore D. & Grossman S. A. (2018). Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). : Oncotarget.

Chicago

Swinnen Lode J, O'Neill Anne, Imus Philip H, Gujar Sachin, Schiff David, Kleinberg Lawrence R, Advani Ranjana H, Dunbar Erin M, Moore Dennis and Grossman Stuart A. 2018. Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). : Oncotarget.

Harvard

Swinnen L. J., O'Neill A., Imus P. H., Gujar S., Schiff D., Kleinberg L. R., Advani R. H., Dunbar E. M., Moore D. and Grossman S. A. (2018). Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). : Oncotarget.

MLA

Swinnen Lode J, O'Neill Anne, Imus Philip H, Gujar Sachin, Schiff David, Kleinberg Lawrence R, Advani Ranjana H, Dunbar Erin M, Moore Dennis and Grossman Stuart A. Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). : Oncotarget. 2018.